How has BridgeBio Pharma's reportable segment — interest income changed year-over-year?

BridgeBio Pharma's reportable segment — interest income increased by 16.0% year-over-year, from $5.39M to $6.25M.

What does reportable segment — interest income mean?

Interest earned on the segment's cash and investment holdings.

How do you interpret reportable segment — interest income?

Higher income suggests a larger cash position or higher interest rate environment.

How does reportable segment — interest income compare across companies?

Standard interest income reporting.

BridgeBio Pharma BBIO Reportable Segment — Interest Income

Similar metrics at other companies

ROIVReportable Segment — Investment Income, Interest

$41.18M-24.6%

LOGIReportable Segment — Interest Income

$14.2M+14.6%

SITMReportable Segment — Investment Income, Interest

$7.31M+70.2%

DKSReportable Segment — Interest Income

$8.7M-53.5%

EXELReportable Segment — Interest Income

$16.13M-15.5%

ADBEReportable Segment — Interest Income

$56M0.0%

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's reportable segment — interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's reportable segment — interest income?: BridgeBio Pharma (BBIO) reported reportable segment — interest income of $6.25M in Q1 2026.
How has BridgeBio Pharma's reportable segment — interest income changed year-over-year?: BridgeBio Pharma's reportable segment — interest income increased by 16.0% year-over-year, from $5.39M to $6.25M.
What does reportable segment — interest income mean?: Interest earned on the segment's cash and investment holdings.
How do you interpret reportable segment — interest income?: Higher income suggests a larger cash position or higher interest rate environment.
How does reportable segment — interest income compare across companies?: Standard interest income reporting.